Article Type
Changed
Thu, 08/31/2023 - 20:25

Key clinical point: Idelalisib demonstrated long-term efficacy in heavily pretreated patients with relapsed or refractory chronic lymphocytic leukemia (CLL), and despite having a relatively higher toxicity profile than other targeted therapeutics, can be used in such patients in the absence of alternative therapies.

Major finding: The overall response rate was 65%, with 1 patient achieving complete remission. At a median follow-up of 33.6 months, the median progression-free survival was 16.4 months (95% CI 10.4-26.3), whereas the median overall survival was not reached. Grade ≥ 3 adverse events occurred in 10 patients. The most common serious adverse event was grade ≥ 3 infection (65%).

Study details: This real-world observational retrospective study included 37 patients with CLL (for up to 2.5 years after idelalisib approval in 2014) who had relapsed after or were refractory to ≥ 1 prior lines of therapy and received idelalisib with or without concomitant rituximab.

Disclosures: This study was supported by grants from AFA Insurance (Australia), the Swedish Cancer Society, and others. Three authors declared receiving research grants or honoraria from various sources. The other authors did not have any conflicts of interest to disclose.

Source: Mattsson A et al. Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients. Eur J Haematol. 2023 (Jul 27). doi: 10.1111/ejh.14065

Publications
Topics
Sections

Key clinical point: Idelalisib demonstrated long-term efficacy in heavily pretreated patients with relapsed or refractory chronic lymphocytic leukemia (CLL), and despite having a relatively higher toxicity profile than other targeted therapeutics, can be used in such patients in the absence of alternative therapies.

Major finding: The overall response rate was 65%, with 1 patient achieving complete remission. At a median follow-up of 33.6 months, the median progression-free survival was 16.4 months (95% CI 10.4-26.3), whereas the median overall survival was not reached. Grade ≥ 3 adverse events occurred in 10 patients. The most common serious adverse event was grade ≥ 3 infection (65%).

Study details: This real-world observational retrospective study included 37 patients with CLL (for up to 2.5 years after idelalisib approval in 2014) who had relapsed after or were refractory to ≥ 1 prior lines of therapy and received idelalisib with or without concomitant rituximab.

Disclosures: This study was supported by grants from AFA Insurance (Australia), the Swedish Cancer Society, and others. Three authors declared receiving research grants or honoraria from various sources. The other authors did not have any conflicts of interest to disclose.

Source: Mattsson A et al. Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients. Eur J Haematol. 2023 (Jul 27). doi: 10.1111/ejh.14065

Key clinical point: Idelalisib demonstrated long-term efficacy in heavily pretreated patients with relapsed or refractory chronic lymphocytic leukemia (CLL), and despite having a relatively higher toxicity profile than other targeted therapeutics, can be used in such patients in the absence of alternative therapies.

Major finding: The overall response rate was 65%, with 1 patient achieving complete remission. At a median follow-up of 33.6 months, the median progression-free survival was 16.4 months (95% CI 10.4-26.3), whereas the median overall survival was not reached. Grade ≥ 3 adverse events occurred in 10 patients. The most common serious adverse event was grade ≥ 3 infection (65%).

Study details: This real-world observational retrospective study included 37 patients with CLL (for up to 2.5 years after idelalisib approval in 2014) who had relapsed after or were refractory to ≥ 1 prior lines of therapy and received idelalisib with or without concomitant rituximab.

Disclosures: This study was supported by grants from AFA Insurance (Australia), the Swedish Cancer Society, and others. Three authors declared receiving research grants or honoraria from various sources. The other authors did not have any conflicts of interest to disclose.

Source: Mattsson A et al. Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients. Eur J Haematol. 2023 (Jul 27). doi: 10.1111/ejh.14065

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: B-Cell Lymphoma, September 2023
Gate On Date
Fri, 02/24/2023 - 22:15
Un-Gate On Date
Fri, 02/24/2023 - 22:15
Use ProPublica
CFC Schedule Remove Status
Fri, 02/24/2023 - 22:15
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article